f Epicardial Adipose Tissue Modulation: A New Horizon for Sodium-Glucose Cotransporter 2 Inhibitors

References

1. Theofilis P. Oikonomou E. Vlachakis P.K. Karakasis P. Dimitriadis K. Sagris M. Pamporis K. Drakopoulou M. Siasos G. Tsioufis K. Tousoulis D. Sodium-glucose cotransporter 2 inhibitors and changes in epicardial adipose tissue: A systematic literature review and meta-analysis. Curr. Vasc. Pharmacol. 2025 23 3 204 212 10.2174/0115701611330060241204062248 39819408
   [Google Scholar]
2. Volčanšek Š. Muzurović E. Epicardial adipose tissue modulation: A new horizon for sodium-glucose cotransporter 2 inhibitors. Curr. Vasc. Pharmacol. 2021 3 1 6 10.2174/0115701611393796250313063902 40114568
   [Google Scholar]
3. Theofilis P. Sagris M. Oikonomou E. Antonopoulos A.S. Siasos G. Tsioufis K. Tousoulis D. Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Res. Clin. Pract. 2022 188 109927 10.1016/j.diabres.2022.109927 35577035
   [Google Scholar]
4. Wang W. Gao Y. Wang J. Ji C. Gu H. Yuan X. Yang S. Wang X. Prognostic value of epicardial adipose tissue in heart failure with mid‐range and preserved ejection fraction: A multicenter study. J. Am. Heart Assoc. 2024 13 24 036789 10.1161/JAHA.124.036789 39673347
   [Google Scholar]
5. Ong Lopez A.M.C. Pajimna J.A.T. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: An updated systematic review and meta-analysis. Sci. Rep. 2024 14 1 2122 10.1038/s41598‑024‑52603‑5 38267513
   [Google Scholar]
6. Cernea S. Onișor D. Roiban A.L. Benedek T. Rat N. Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes. World J. Cardiol. 2024 16 10 580 594 10.4330/wjc.v16.i10.580 39492975
   [Google Scholar]
7. Theofilis P. Oikonomou E. Karakasis P. Pamporis K. Dimitriadis K. Kokkou E. Lambadiari V. Siasos G. Tsioufis K. Tousoulis D. FGF21 Analogues in patients with metabolic diseases: Systematic review and meta‐analysis of randomised controlled trials. Liver Int. 2025 45 3 70016 10.1111/liv.70016 39898512
   [Google Scholar]